John-Paul Gallivan

SVP, Head of Development

John-Paul Gallivan, currently serves as our Senior Vice President and Head of Development at Onco3R and has over 15 years of experience in the biotech and pharmaceutical industry.

He joins Onco3R from Galapagos, where he was VP and Program Leader for small molecules and antibodies in the development organization.

Prior to that, John-Paul worked at NuCana, a clinical stage, NASDAQ-listed biotech, as VP Clinical Development and Medical Affairs and SVP of Strategy and Lifecycle Management.

John-Paul also gained extensive experience working in a variety of leadership positions in medical, development and strategic functions at Roche, Boehringer-Ingelheim and BMS where he worked on projects in oncology, immunology and infectious diseases.

John-Paul holds a B.Sc in medical microbiology from the University of Edinburgh, and an M.Sc and a Ph.D in virology from Imperial College London.